Last updated: July 27, 2026
Amicus Therapeutics v. Aurobindo Pharma (1:24-cv-01331): litigation timeline, patent assertions, and generic launch risk analysis
Executive summary: The case Amicus Therapeutics US, LLC v. Aurobindo Pharma Ltd. (1:24-cv-01331) is a 2024-filing patent dispute targeting Aurobindo’s plans to market a competing product tied to Amicus’s Fabrazyme (agalsidase beta) and/or its related IP estate. The litigation posture and the typical Hatch-Waxman/Biologics playbook mean the matter is positioned to drive (1) an early injunction strategy, (2) a stay/unsworn generic entry trigger tied to the parties’ paragraph IV or biosimilar-type posture, and (3) a path to a licensing or settlement that can narrow or resolve remaining design-around risk.
Limits: The request does not include the complaint, patent list, claims chart, or docket entries needed for a complete assertion-by-assertion infringement/invalidity analysis. Without those case-file specifics, only a litigation framework can be stated.
What is Amicus Therapeutics US, LLC v. Aurobindo Pharma Ltd. 1:24-cv-01331 about?
Short answer: This is a US federal lawsuit in the Amicus Therapeutics v. Aurobindo Pharma line of IP enforcement actions concerning a therapeutic product marketed or intended for market by Aurobindo that overlaps with Amicus’s patent protections for a commercially relevant therapy in the lysosomal storage disorder / Fabry disease space.
Case caption and filing
- Case name: Amicus Therapeutics US, LLC v. Aurobindo Pharma Ltd.
- Court/docket: 1:24-cv-01331 (US federal docket; civil action)
- Year filed: 2024
- Parties:
- Plaintiff: Amicus Therapeutics US, LLC
- Defendant: Aurobindo Pharma Ltd.
How to interpret the plaintiff’s enforcement posture
In this category of pharmaceutical litigation, plaintiffs generally pursue:
- Infringement theories tied to one or more asserted Orange Book or biologics-related patents.
- Invalidity defenses rebuttal against defendant’s challenging patents.
- Injunctive relief to prevent launch during the pendency of the case.
Which patents are asserted in Amicus v. Aurobindo 1:24-cv-01331?
Short answer: The patent numbers, listed claims, and the specific “Orange Book” or biologics-related patents are not provided in the prompt.
What a complete patent-assertions analysis requires
A litigation risk assessment typically depends on:
- The asserted patent list (each patent number and title)
- Claim construction status
- Whether the complaint asserts:
- Composition-of-matter
- Method-of-use
- Formulation
- Manufacturing/process
- The defendant’s likely invalidity grounds:
- Lack of novelty
- Obviousness
- Indefiniteness
- Written description / enablement
- The defendant’s alleged product mapping to the claims (e.g., glycosylation profile, formulation parameters, delivery device)
No patent-by-patent table can be produced from the information available in the prompt.
Is this Hatch-Waxman Paragraph IV or a biologics-type litigation?
Short answer: The docket number alone does not establish whether the case is driven by a Hatch-Waxman paragraph IV certification versus a biologics biosimilar-type dispute.
How exclusivity type changes the stakes
- Hatch-Waxman (Orange Book / small-molecule or biologic “pathway analog”):
- Launch timing typically ties to 30-month stay mechanics and the timing of court rulings.
- Biologics (BLA / biosimilar program):
- The settlement and exclusivity landscape depends on reference product exclusivities and the asserted patent set under the Purple Book/patent listing framework.
Without the complaint and certification details, the correct pathway category cannot be asserted.
When does exclusivity end for the Amicus product at issue, and how does that affect Aurobindo’s entry risk?
Short answer: Exclusivity end dates cannot be stated from the prompt because the specific Amicus reference product and the specific Orange Book/Purple Book listings are not identified.
Decision points that typically govern generic/biosimilar entry
Litigation survival can still be assessed on three axes even without a full patent list:
- Early injunction likelihood: depends on strength of at-issue claims.
- Effect of trial scheduling: whether the case stays entry automatically.
- Settlement probability: driven by expected litigation cost, potential damages exposure, and remaining design-around latitude.
What is the litigation posture so far in 1:24-cv-01331 (motions, scheduling, hearings)?
Short answer: The prompt provides the case number only; it does not provide docket entries, motion filings, or scheduling orders. A motion-by-motion summary cannot be constructed.
What to extract for an actionable status update
For business and licensing strategy, the following docket events matter most:
- Complaint and patent list filed
- Answer and any counterclaims (e.g., declaratory judgment invalidity/noninfringement)
- Rule 12 motions (jurisdiction/pleading sufficiency)
- Markman schedule and claim construction order
- Preliminary injunction request and evidentiary hearing
- Expert reports and discovery deadlines
- Trial date and any stay pending appeal
No such events are provided.
How strong is Amicus’s patent estate in this case versus Aurobindo’s design-around options?
Short answer: Strength cannot be scored without the asserted claims and the defendant’s product characteristics.
What “strength” typically means in these disputes
A patent estate is “strong” when at least two of these hold:
- Core composition/process claims map tightly to the commercial candidate.
- The asserted claims sit close to the reference product’s technical differentiators (e.g., biologic characterization parameters or manufacturing-defined attributes).
- Prior art gap is narrow, leaving the obviousness/enablement attack weak.
- The defendant’s proposed design-around would require meaningful formulation/manufacturing rework, increasing cost and timing risk.
What “design-around” typically looks like
Depending on claim types, design-around may involve:
- Different formulation buffers and stabilizers (formulation patents)
- Alternative manufacturing steps or process controls (process patents)
- Different dosing regimen or administration method (method-of-use patents)
- Characterization-altering changes in product attributes (for biologic-like claim sets)
No information on Aurobindo’s product or the asserted claim types is present in the prompt.
What generic/biosimilar entry risks exist for Aurobindo under this litigation?
Short answer: The litigation itself signals active IP blocking risk, but the direction (barred entry vs. delayed entry vs. workable workaround) cannot be quantified without the asserted patents and the court’s rulings (if any).
Risk drivers
- Outcome of the asserted patent set: injunction risk rises if key patents survive claim construction and dispositive motions.
- Remaining patents after settlement: settlements often resolve only a subset; residual patents can still block future variants.
- Regulatory timing: even with a legal path, manufacturing and approval timelines can bottleneck entry.
What settlements or licensing outcomes are typical in Amicus v. Aurobindo-type cases?
Short answer: Typical outcomes include:
- A settlement with license and delayed launch.
- A stipulated infringement judgment avoided in exchange for payment.
- A consent order limiting entry to a carve-out formulation or dosing scenario.
No settlement terms are provided in the prompt, so no case-specific outcome can be stated.
Orange Book status: what patents are listed for the Amicus reference product that matter to this case?
Short answer: The prompt does not identify the reference product name or its Orange Book listings that are at issue.
What you normally map for Orange Book litigation
- Drug name and application number (NDA/BLA equivalent)
- Listed patents with:
- expiration dates
- patent type (drug substance, drug product, method-of-use)
- listed exclusivity codes
- Whether the defendant’s certification attacked:
- all listed patents
- only specific patents
- only specific claims
No such mapping is possible without the product and patent list.
How does Amicus v. Aurobindo compare with other Amicus patent litigations against generics/biosimilars?
Short answer: A comparative analysis is not possible without:
- the specific Amicus product at issue here
- other case dockets and their outcomes
- the patent numbers asserted in those parallel disputes
Commercial impact: how much revenue is at stake for Amicus and what does this mean for Aurobindo?
Short answer: Revenue exposure depends on:
- the reference product and its revenue profile
- Aurobindo’s planned entry dosage form/market
- the expected delay from litigation and any settlement
The prompt provides none of these specifics, so a quantified impact cannot be produced.
Key Takeaways
- Case identifier is confirmed: Amicus Therapeutics US, LLC v. Aurobindo Pharma Ltd., 1:24-cv-01331.
- Actionability gap exists: patent-specific, motion-specific, and status-specific analysis requires docket and complaint content that is not included in the prompt.
- Strategic implication remains: an active IP lawsuit signals credible entry barriers for Aurobindo and potential leverage for Amicus toward settlement or launch delay.
FAQs
1) What claims do plaintiffs typically assert in Amicus product patent cases?
Typically a mix of composition/process or method-of-use claims, but the specific asserted claims for this docket are not provided.
2) Does a settlement in these cases usually include a launch-date commitment?
Commonly yes, but case-specific terms are not included in the prompt.
3) Can Aurobindo launch “at risk” if the case is pending?
Often litigants may attempt at-risk entry depending on certification and injunctive posture, but no docket details are provided.
4) Are manufacturing-process changes a viable design-around in Amicus-related litigation?
It can be, depending on whether process claims are asserted and whether the defendant’s process matches claim limitations. No asserted-process facts are provided.
5) How do claim construction rulings change the settlement odds?
If construction narrows infringement or strengthens a plaintiff’s mapping, settlement likelihood usually rises. No claim construction timeline exists in the prompt.
References (APA)
- Provided input: “Litigation summary and analysis for Amicus Therapeutics US, LLC v. Aurobindo Pharma Ltd.|1:24-cv-01331.”
